BTF hosted the 2022 Highlights from ASH on Feb 19, 2022 in Coeur d’Alene, Idaho

The 2022 Highlights Highlights of ASH was hosted on February 19, 2022 at The Coeur d’Alene Resort, Coeur d’Alene, Idaho. The Binaytara Foundation Education Academy hosted an in-person Conference, 2022 Highlights Highlights of ASH, on February 19, 2022 at the Coeur d’Alene Resort, Coeur d’Alene, Idaho to review the Highlights from the American Society of Clinical Oncology 63rd Annual Meeting that was held in December 2021. The conference was chaired by Dr. Srinivas Tantravahi from the University of Utah and included reviews of important abstracts on both malignant hematology and benign blood disorders.

Dr. Shaji Kumar from Mayo Clinic, Dr. George Rodgers from University of Utah, Dr. Doris Quon from the Orthopedic Hemophilia Institute of the University of Utah, Dr. Parameswaran Veugopal from Rush University Medical Center, Dr. Jacob Appelbaum from the University of Washington and several other hematology experts participated in the this CME accredited hematology conference.

Pictures from the 2022 Highlights of ASH in Coeur d’Alene, Idaho

The live 2022 Highlights of ASH meeting (ASH Review) was recorded, and is available as a self-paced enduring activity (recorded webcast) on the Binaytara Foundation Education Academy. Anyone who was unable to attend the live, in-person meeting can watch the recorded webcast from this ASH Review meeting and claim free oncology CME. Healthcare providers who participated in the live version of this ASH Review meeting in Coeur d’Alene can also review the webcast but can only claim CME credits for one activity.

All self-paced CME activities provided by the Binaytara Foundation are free for healthcare providers not employed by the biopharma industry.

The 2022 Highlights of ASH is the 3rd Annual ASH review organized by the Binaytara Foundation. Based on the identified educational needs, the Binaytara Foundation plans and implements educational activities that are relevant for our target population. In 2021, we provided continuing education to 700+ healthcare providers through our in-person and online platforms.

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago